Control of bleeding in patients with haemophila A with inhibitors: A systematic review

Haemophilia

Volumn 9, Issue 4, 2003, Pages 464-520

  Jones, M Lloyd ^a   Wight, J ^a   Paisley, S ^a   Knight, C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Acute bleeding; FVIII; Haemophilia A; Inhibitors; Prothrombin complex concentrates; Recombinant FVIIa; Systematic review

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9 COMPLEX; CIMETIDINE; CYCLOPHOSPHAMIDE; HYDROCORTISONE; PROPLEX SX; PROTHROMBINEX; PROTHROMBLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ABDOMINAL PAIN; ANGINA PECTORIS; ANTIBODY TITER; BLEEDING; CHILL; CLINICAL TRIAL; DATA ANALYSIS; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DROWSINESS; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; FEVER; HAIR LOSS; HEADACHE; HEART INFARCTION; HEMOPHILIA A; HOT FLUSH; HUMAN; HYPOTENSION; INFORMATION PROCESSING; LETHARGY; LEUKOPENIA; LOW BACK PAIN; NAUSEA; PAIN; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; RETINA VEIN OCCLUSION; REVIEW; SURGICAL INFECTION; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; THROMBOPHLEBITIS; THROMBOSIS; TREATMENT OUTCOME; URTICARIA; VERTIGO; VIRUS INFECTION; WOUND HEALING IMPAIRMENT;

EID: 0038383602     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00782.x     Document Type: Review

References (91)

1. Zech R, Strother SV. Maintenance of hemostasis during exodontia in two hemophiliacs with factor VIII inhibitors. J Oral Maxillofac Surg 1983; 41: 53-6.
2. Scharf R, Kucharski W, Nowak T. Surgery in hemophilia A patients with factor VIII inhibitor: 10-year experience. World J Surg 1996; 20: 1171-81.
3. Sindet-Pedersen S, Stenbjerg S. Effect of local anti-fibrinolytic treatment with tranexamic acid in hemophiliacs undergoing oral surgery. J Oral Maxillofac Surg 1986; 44: 704-7.
4. Hanna WT, Madigan RR, Miles MA, Lange RD. Activated factor IX complex in treatment of surgical cases of hemophilia A with inhibitors. Thromb Haemost 1981; 46: 638-41.
5. Shurafa M, MacIntosh RB. Management of dental extractions in two hemophilia A patients with factor VIII inhibitor. J Oral Maxillofac Surg 1987; 45: 698-701.
6. NHS Centre for Reviews and Dissemination. Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for Carrying Out or Commissioning Reviews, 2nd edn. York: NHS Centre for Reviews and Dissemination, University of York, 2001 (CRD Reports 4).
7. Centre for Evidence Based Medicine. Levels of Evidence and Grades of Recommendation. http://www.cebm.jr2.ox.ac.uk, 2001.
8. Ekert H, Price DA, Lane JL, Dean FL. A randomized study of factor VIII or prothrombin complex concentrate infusions in children with haemophilia and antibodies to factor VIII. Aust NZ J Med 1979; 9: 241-4.
9. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med 1980; 303: 421-5.
10. Gomperts ED, Fannon RB, Lee ML et al. PROPLEX vs. PROPLEX SX: a controlled double blind study of the effectiveness in treating acute hemarthroses in hemophilia A patients with inhibitors to factor VIII. Thromb Res 1986; 42: 789-96.
11. Lusher JM, Blatt PM, Penner JA et al. Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983; 62: 1135-8.
12. Lusher JM, Roberts HR, Davignon G et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998; 4: 790-8.
13. Prentice CR. Comparison of factor VIII and prothrombin complex concentrates in the treatment of inhibitor patients. Prog Clin Biol Res 1984; 150: 197-206.
14. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
15. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305: 717-21.
16. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
17. Kasper CK. Human factor VIII for bleeding in patients with inhibitors. Vox Sang 1999; 77(Suppl. 1): 47-8.
18. Francesconi M, Korninger C, Thaler E, Niessner H, Hocker P, Lechner K. Plasmapheresis: its value in the management of patients with antibodies to factor VIII. Haemostasis 1982; 11: 79-86.
19. Gatti L, Mannucci PM. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies. Thromb Haemost 1984; 51: 379-84.
20. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 2000; 26: 425-32.
21. Cudzinowski L. Circulating antibodies in factor VIII deficiency hemophilia: report of case. J Dent Child 1979; January-February: 54-6.
22. Brackmann HH, Aygoren E, Scharrer I, Schwaab R, Hammerstein U, Oldenburg J. Two years' experience with two recombinant factor VIII concentrates. Blood Coagul Fibrinolysis 1993; 4: 421-4.
23. Blatt PM, White GC, McMillan CW, Roberts HR. Treatment of anti-factor VIII antibodies. Thromb Haemost 1977; 38: 514-23.
24. Rizza CR. The management of haemophiliacs who have antibodies to factor VIII. Scand J Haematol 1984; 40(Suppl. 33): 187-93.
25. Kernoff PB. Rationale and evolution of therapy with porcine factor VIII:C. Am J Med 1991; 91: 20S-2S.
26. Gringeri A, Santagostino E, Tradati F, Giangrande PL, Mannucci PM. Adverse effects of treatment with porcine factor VIII. Thromb Haemost 1991; 65: 245-7.
27. Hay CR, Lozier JN, Lee CA et al. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey. Thromb Haemost 1996; 75: 25-9.
28. Ciavarella N, Antoncecchi S, Ranieri P. Efficacy of porcine factor VIII in the management of haemophiliacs with inhibitors. Br J Haematol 1984; 58: 641-8.
29. Ciavarella N, Antoncecchi S, Ettorre C, Ranieri P. Clinical experience with porcine factor VIII (Hyate-C) in 10 hemophilia-A patients with inhibitors. Ricerca in Clinica e in Laboratorio 1986; 16: 85.
30. Brettler DB, Forsberg AD, Levine PH et al. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Int Med 1989; 149: 1381-5.
31. Hilgartner MW. The prophylactic use of porcine factor VIII. Semin Hematol 1994; 31: 39-40.
32. Hay CR, Lozier JN, Lee CA et al. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects. Semin Hematol 1994; 31(Suppl. 4): 20-5.
33. Hay CRM, BoltonMaggs PBM, Castaman G, Goldsmith JC, DiMichele D. Continuous infusion of porcine factor VIII in patients with haemophilia A and inhibitors. Br J Haematol 1996; 93: 228.
34. Abildgaard CF, Penner JA, Watson-Williams EJ. Anti-inhibitor coagulant complex (Autoplex) for treatment of factor VIII inhibitors in hemophilia. Blood 1980; 56: 978-84.
35. Fujimura Y, Sugimoto M, Niinomi K et al. Removal of a calcaneus pseudotumor in a factor VIII deficient patient with inhibitor using autoplex. J Nare Med Assoc 1984; 35: 291-7.
36. Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). Br J Haematol 2000; 111: 78-90.
37. Lusher JM. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors - benefits and limitations. Semin Hematol 1994; 31(Suppl. 4): 49-52.
38. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM. Prothrombin complex concentrates in hemophiliacs with inhibitors - a multicenter therapeutic trial. Trans Assoc Am Physic 1980; 93: 175-81.
39. Eyster ME, Spero JA, Catalano PM et al. Inhibitor treatment using unactivated prothrombin complex concentrates: the Pennsylvania experience - 1978-1982. Prog Clin Biol Res 1984; 150: 309-22.
40. Kelly P, Penner JA. Antihemophilic factor inhibitors. Management with prothrombin complex concentrates. JAMA 1976; 236: 2061-4.
41. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998; 9: 119-28.
42. Ekert H, Smibert E, Exton J. Long-term results of the treatment of children with factor VIII inhibitors with prothrombin-complex concentrates. Med J Aust 1987; 147: 230-3.
43. Kasper CK. Effect of prothrombin complex concentrates on factor VIII inhibitor levels. Blood 1979; 54: 1358-68.
44. Kantrowitz JL, Lee ML, McClure DA, Kingdon HS, Thomas WR. Early experience with the use of anti-inhibitor coagulant complex to treat bleeding in hemophiliacs with inhibitors to factor VIII. Clin Ther 1987; 9: 405-19.
45. Hilgartner M, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990; 30: 626-30.
46. Hilgartner MW, Natterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-40.
47. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113-9.
48. Agrestini F, Solinas S, Marinelli M, Avvisati G, Badia D, Mazzucconi MG. Activated prothrombin complex concentrates in dental extractions and oral and minor surgery in hemophiliacs with high-titer inhibitors. In: Mariani G, Russo MA, Mandelli F, eds. Activated Prothrombin Complex Concentrates. New York: Praeger, 1982: 168-75.
49. White GC. Seventeen years' experience with Autoplex/Autoplex T: evaluation of inpatients with severe haemophilia A and factor VIII inhibitors at a major haemophilia centre. Haemophilia 2000; 6: 508-12.
50. Wilde JT. The Use of APCCs in Haemophilia Patients with Inhibitors, 2001. Unpublished conference presentation. Evidence Based Hemostases, Dublin, November 2001.
51. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
52. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104: 22-6.
53. Schulman S. Safety, efficacy and lessons from continuous infusion with rFVIIa. Haemophilia 1998; 4: 564-7.
54. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 1999; 5: 253-9.
55. Negrier C, Lienhart A. Overall experience with NovoSeven. Blood Coagul Fibrinolysis 2000; 11 (Suppl. 1):S19-S24.
56. Seremetis SV. The clinical use of factor VIIa in the treatment of factor VIII inhibitor patients. Semin Hematol 1994; 31(Suppl. 4): 53-5.
57. Lusher JM. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis 2000; 11(Suppl. 1): S45-S49.
58. Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol 1998; 63(Suppl.): 7-10.
59. Brackmann HH, Effenberger E, Hess L, Schwaab R, Oldenburg J. NovoSeven in immune tolerance therapy. Blood Coagul Fibrinolysis 2000; 11(Suppl. 1): S39-S44.
60. Ingerslev J, Thykjaer H, Scheibel E. Approaches towards successful home treatment in patients with inhibitors. Eur J Haematol 1998; 63(Suppl.): 11-4.
61. Laurian Y, Goudemand J, Negrier C et al. Use of recombinant activated factor VII as first-line therapy for bleeding episodes in haemophiliacs with factor VIII or IX inhibitors (NOSEPAC study). Blood Coagul Fibrinolysis 1998; 9(Suppl. 1): 155-6.
62. Shapiro AD. Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors. Semin Thromb Hemost 2000; 26: 413-9.
63. Bech RM. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis 1996; 26(Suppl. 1): 135-8.
64. McPherson J, Teague L, Lloyd J et al. Experience with recombinant factor VIIa in Australia and New Zealand. Haemostasis 1996; 26(Suppl. 1): 109-17.
65. Arkin S, Blei F, Fetten J et al. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis 2000; 11: 255-9.
66. Liebman HA, Chediak J, Fink KI, Galvez AG, Shah PC, Sham RL. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII. Am J Hematol 2000; 63: 109-13.
67. Lusher JM. Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 1996; 26(Suppl. 1): 124-30.
68. Darby SC, Ewart DW, Giangrande PLF, Dolin PJ, Spooner RJD, Rizza CR. Mortality before and after HIV-infection in the complete UK population of hemophiliacs. Nature 1995; 377: 79-82.
69. Rosendaal FR, Varekamp I, Smit C et al. Mortality and causes of death in Dutch hemophiliacs, 1973-86. Br J Haematol 1989; 71: 71-6.
70. Rice KM, Savidge GF. NovoSeven (recombinant factor VIIa) in central nervous systems bleeds. Haemostasis 1996; 26(Suppl. 1): 131-4.
71. Arkin S, Cooper HA, Hutter JJ et al. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the Novoseven emergency-use program. Haemostasis 1998; 28: 93-8.
72. Ingerslev J, Freidman D, Gastineau D et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26(Suppl. 1): 118-23.
73. DiMichele D. The use of recombinant factor VIIa (Novoseven) for central catheter insertion: an international experience. Thromb Haemost 1997; 77(S): 167.
74. Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus Med Rev 1993; 7: 78-83.
75. Brackmann HH, Effenberger W, Hess L, Schwaab R, Oldenburg J. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)? Eur J Haematol 1998; 63(Suppl.): 18-23.
76. Schulman S. Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring, and cost effectiveness. Semin Thromb Hemost 2000; 26: 421-4.
77. Kenet G, Lubetsky A, Luboshitz J, Varon D, Martinowitz U. A single mega dose of rFVIIa for treatment of hemophilia patients with inhibitors. Blood 2000; 96: 1147.
78. Chuansumrit A, Isarangkura P, Angchaisuksiri P et al. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection. Haemophilia 2000; 6: 61-5.
79. Kenet G, Lubetsky A, Gitel S, Luboshitz J, Varon D, Martinowitz U. Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VII. Blood Coagul Fibrinolysis 2000; 11(Suppl. 1): S35-S38.
80. Ettingshausen CE, Auerswald G, Auberger K, Saguer IM, Kreuz W. Efficacy and safety of continuous infusion of recombinant factor VIIa in pediatric hemophilia A patients with high titer inhibitors. Blood 1999; 94: 1052.
81. Smith MP, Ludlam CA, Collins PW et al. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII. Thromb Haemost 2001; 86: 949-53.
82. Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001; 86: 954-8.
83. Sultan Y, Maisonneuve P, Sylvestre R. Plasma exchange in the treatment of hemophiliacs with antibodies to factor VIII. In: Mariani G, Russo MA, Mandelli F, eds. Activated Prothrombin Complex Concentrates. New York: Praeger, 1982: 55-9.
84. Wensley RT, Stevens RF, Burn AM, Delamore IW. Plasma exchange and human factor VIII concentrate in managing haemophilia A with factor VIII inhibitors. BMJ 1980; 281: 1388-9.
85. Watt RM, Bunitsky K, Faulkner EB et al. Treatment of congenital and acquired hemophilia patients by extracorporeal removal of antibodies to coagulation factors - a review of United States clinical studies. Transfusion Science 1992; 13: 233-53.
86. Fernandez RA, Gonzalez SQ, Murillo CM, Garcia VD, Moyado HR, Jaloma JC. Treatment of patients with hemophilia A and inhibitors to factor FVIII with cimetidine. Arch Med Res 1996; 27: 15-8.
87. Ruggeri ZM, Mannucci PM, Allain JP, Frommel D. Preliminary trial of cyclophosphamide in the management of hemophiliacs with factor VIII inhibitors. Annals NY Acad Sci 1975; 240: 412-8.
88. Dormandy KM, Sultan Y. The suppression of factor VIII antibodies in haemophilia. Pathol Biol (Paris) 1975; 23(Suppl.): 17-23.
89. Slocombe GW, Newland AC, Colvin MP, Colvin BT. The role of intensive plasma exchange in the prevention and management of haemorrhage in patients with inhibitors to factor VIII. Br J Haematol 1981; 47: 577-85.
90. Blatt PM, Pearsall AH, Givhan EG, Hallum CE, Roberts HR, Webster WP. Haemostatic failure of prothrombin complex concentrates during elective dental procedure. Thromb Haemost 1980; 42: 1604-6.
91. Hind D, Lloyd Jones M. Management of inhibitors in people with haemophilia A (Cochrane Review). The Cochrane Library (to be published in 2003). Oxford: Update Software 2003.